Drug intelligence / Profile preview

KAN-ONCO-02

Development stage: Preclinical
Lead developer: Kantify
Modality: Small Molecules

Overview

KAN-ONCO-02 is a preclinical-stage small molecule drug candidate being developed by Kantify for the treatment of soft tissue sarcoma. Discovered using Kantify's proprietary Sapian™ AI platform, the drug is designed to modulate multiple novel oncology targets. As of early 2024, the program is fully owned by Kantify and is undergoing preclinical validation. The specific biological targets and detailed mechanism of action have not been publicly disclosed, but the candidate is part of a broader pipeline of AI-discovered small molecules aimed at addressing unmet needs in oncology.

Beyond the preview

Go deeper on KAN-ONCO-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KAN-ONCO-02.

Explore the full profile